Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP

The Journal of clinical endocrinology and metabolism5 Aug 2008Cited by 152 (Europe PMC)

PMID18682511PMCIDPMC5399468DOI10.1210/jc.2008-0353PepBankPUB-18682511

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialSafety outcome
In women with osteoporosis previously treated with bisphosphonates, teriparatide was well tolerated.
In plain wordsIn women with osteoporosis previously treated with bisphosphonates, teriparatide was well tolerated.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide was well tolerated.
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
Report a problemFND-1868251106

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In women receiving teriparatide, prior risedronate users had greater PINP increases than prior alendronate users after 3 months.
In plain wordsIn women receiving teriparatide, a bone formation marker increased more after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP increase
Study
n: not reported in source
Comparator
Prior alendronate group receiving teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
PINP increase
86 ng/ml
prior risedronate
PINP increase
61.2 ng/ml
prior alendronate
Source sentences
Summary
In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean +/- se, 86.0 +/- 5.6 vs. 61.2 +/- 5.3 ng/ml, respectively; P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1868251101
03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In women receiving teriparatide, other bone turnover markers showed similar greater responses after prior risedronate than after prior alendronate.
In plain wordsIn women receiving teriparatide, other bone turnover markers responded more after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOther bone turnover marker changes
Study
n: not reported in source
Comparator
Prior alendronate group receiving teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Findings were similar for the other bone turnover markers.
4 context sentences(design, population, supporting numbers)
Summary · context
In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean +/- se, 86.0 +/- 5.6 vs. 61.2 +/- 5.3 ng/ml, respectively; P < 0.001).
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1868251102
04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In women receiving teriparatide, areal BMD changes were greater after prior risedronate than after prior alendronate.
In plain wordsIn women receiving teriparatide, bone density changes were greater after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAreal BMD change
Study
n: not reported in source
Comparator
Prior alendronate group receiving teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1868251103
05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In women receiving teriparatide, trabecular spine volumetric BMD changes were greater after prior risedronate than after prior alendronate.
In plain wordsIn women receiving teriparatide, spine volumetric bone density changed more after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular spine volumetric BMD change
Study
n: not reported in source
Comparator
Prior alendronate group receiving teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1868251104
06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialOther
In women receiving teriparatide, early bone turnover marker changes correlated with later trabecular spine volumetric BMD changes.
In plain wordsIn women receiving teriparatide, early bone marker changes were linked to later spine bone density changes.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMarker association with volumetric BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spearman correlation
0.45 r
early markers versus 12-month volumetric BMD
Source sentences
Summary
Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.
Summary · context
Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months.
Summary · context
The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1868251105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00130403

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Sanofin = 290Mar 2004 to Mar 2007

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 11 Jan 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.